Key Points
- Researchers have developed a simple form for tracking and reporting patient experiences of focused ultrasound neuromodulation.
- The template complements existing safety measures while supporting data comparison across studies.
As clinical research using focused ultrasound neuromodulation progresses, investigators are working to ensure that its safety and tolerability are measured in consistent, meaningful ways. A new article in Brain Stimulation proposes a standardized framework for tracking and reporting participant experiences during low-intensity focused ultrasound (LIFU) neuromodulation. The template is a practical tool that could help researchers compare findings across studies and better understand patient-reported effects.
Neuromodulation with LIFU is a noninvasive approach that uses acoustic energy to temporarily influence brain activity. Unlike ablative focused ultrasound procedures, low-intensity neuromodulation is designed to produce reversible effects without permanent tissue injury. When protocols are appropriately designed and follow expert recommendations, the risk of tissue injury is considered low.
Even so, as the field grows, researchers need reliable ways to document how participants feel before and after treatment. Previous studies have reported that adverse events are generally mild, temporary, and well tolerated, often including symptoms such as headache, scalp sensations, or discomfort at the treatment site. However, each study uses different methods to collect and report this information. Some have relied on spontaneous reports, while others have used informal interviews or symptom checklists. This variability makes it difficult to compare results across studies or identify patterns that may be important for safety, tolerability, or dose selection.
2026;19(3):103104.
To address this gap, the authors propose a simple event-reporting form for LIFU neuromodulation studies. The form is designed to capture participant-experienced effects across several domains, including physical sensations, sensory changes, motor effects, cognitive symptoms, emotional responses, sleep-related changes, and possible autonomic responses. The authors recommend administering the form before focused ultrasound neuromodulation to establish a baseline, and again after the procedure. They also suggest using the form in sham-controlled studies in both active and sham treatment groups so investigators can better distinguish treatment-related effects from background symptoms or participant expectations.
The proposed framework also reflects a broader push within the focused ultrasound field to improve consistency in how safety data are collected and shared.
“This work aligns closely with the Focused Ultrasound Foundation’s ongoing efforts to advance reporting standards across the field,” said Frédéric Padilla, PhD, Director of Applied Physics Research at the Focused Ultrasound Foundation. “By complementing technical reporting guidelines with a standardized approach to documenting participant-reported experiences, it helps create a more complete picture of treatment safety. Over time, combining these data with detailed treatment parameters could enable researchers to identify factors associated with side effects and refine protocols to improve the safety and effectiveness of focused ultrasound neuromodulation.”
Greater consistency in adverse-event reporting will make it easier to compare results across studies, identify unexpected effects, and support future research and meta-analyses. As LIFU neuromodulation expands across neurological and psychiatric applications, standardized reporting will help strengthen transparency and support the responsible advancement of the technology.
See Brain Stimulation (Open Access)
Related Stories
Elevating the Discussion: Focused Ultrasound Safety Standards January 2026
Advances in Focused Ultrasound: 2024 Review on Bioeffects and Safety January 2025